163 related articles for article (PubMed ID: 24255570)
1. Criminal or bystander: imatinib and second primary malignancy in GIST patients.
Kanda T
Chin J Cancer Res; 2013 Oct; 25(5):490-2. PubMed ID: 24255570
[No Abstract] [Full Text] [Related]
2. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
3. Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.
Mohammadi M; Jansen-Werkhoven TM; Ijzerman NS; den Hollander D; Bleckman RF; Oosten AW; Desar IME; Reyners AKL; Steeghs N; Gelderblom H
Target Oncol; 2022 Nov; 17(6):627-634. PubMed ID: 36374447
[TBL] [Abstract][Full Text] [Related]
4. Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review.
Hecker A; Hecker B; Bassaly B; Hirschburger M; Schwandner T; Janssen H; Padberg W
World J Surg Oncol; 2010 Jun; 8():47. PubMed ID: 20515511
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis.
Bischof DA; Dodson R; Jimenez MC; Behman R; Cocieru A; Blazer DG; Fisher SB; Squires MH; Kooby DA; Maithel SK; Groeschl RT; Gamblin TC; Bauer TW; Karanicolas PJ; Law C; Quereshy FA; Pawlik TM
J Gastrointest Surg; 2015 Jun; 19(6):1022-8. PubMed ID: 25731828
[TBL] [Abstract][Full Text] [Related]
6. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
7. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
8. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
9. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
10. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
Hatoum HT; Lin SJ; Sasane M; Trent JC
Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
[TBL] [Abstract][Full Text] [Related]
12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
13. Current clinical strategy for imatinib-resistant gastrointestinal stromal tumors.
Yamamoto M; Konno H
Clin J Gastroenterol; 2009 Jun; 2(3):137-142. PubMed ID: 26192283
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH
Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
16. Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients.
Duffaud F; Even C; Ray-Coquard I; Bompas E; Khoa-Huynh T; Salas S; Cassier P; Dufresne A; Bonvalot S; Ducimetiere F; Le Cesne A; Blay JY
Clin Sarcoma Res; 2012 Sep; 2(1):11. PubMed ID: 22950685
[TBL] [Abstract][Full Text] [Related]
17. Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.
Zalcberg JR; Desai J
Asia Pac J Clin Oncol; 2012 Mar; 8(1):43-52. PubMed ID: 22369443
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
19. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
20. Urgent surgery for intraperitoneal bleeding from GIST during imatinib therapy.
Enomoto T; Kanda T; Yajima K; Hirota S; Matsuki A; Kosugi S; Kato T; Ajioka Y; Hatakeyama K
Clin J Gastroenterol; 2010 Apr; 3(2):73-7. PubMed ID: 26189998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
